YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc. presented data that sets a new standard for EGFR-T790M resistance mutation detection in lung cancer, with the highest sensitivity reported ...

Exosome Diagnostics recently announced the launch of ExoDx Lung(ALK), a liquid biopsy platform that allows for non-invasive detection of biomarkers and potentially negates the need for a tissue biopsy ...

Exosome Diagnostics is trotting out promising data for its lung cancer liquid biopsy test, a week after reeling in new funds to support development of its liquid biopsy technology and build out its ...

Earlier this year, Exosome Diagnostics said that it would scout out deals with biopharma partners to gain ground with its liquid biopsy tests. Now, the company is ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. The investigators purified and marked high levels of exosomes from blood of ...

Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 ...

MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced data demonstrating the ability of its plasma ...

Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore), or EPI, through FedMed, Inc., a ...